Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $1.8 million.

  • Lyra Therapeutics' Shares Outstanding (Weighted Average) rose 3503.69% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 3503.69%. This contributed to the annual value of $65.1 million for FY2024, which is 3073.95% up from last year.
  • Latest data reveals that Lyra Therapeutics reported Shares Outstanding (Weighted Average) of $1.8 million as of Q3 2025, which was up 3503.69% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Lyra Therapeutics' Shares Outstanding (Weighted Average) registered a high of $65.8 million during Q1 2025, and its lowest value of $1.3 million during Q3 2024.
  • Over the past 5 years, Lyra Therapeutics' median Shares Outstanding (Weighted Average) value was $30.2 million (recorded in 2022), while the average stood at $29.1 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first skyrocketed by 18324.67% in 2022, then crashed by 9770.14% in 2024.
  • Quarter analysis of 5 years shows Lyra Therapeutics' Shares Outstanding (Weighted Average) stood at $13.0 million in 2021, then skyrocketed by 132.83% to $30.2 million in 2022, then surged by 64.72% to $49.8 million in 2023, then soared by 30.74% to $65.1 million in 2024, then plummeted by 97.29% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $1.3 million for Q2 2025, and $65.8 million during Q1 2025.